secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001104659-24-073418
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Entero Therapeutics transitions COO Jack Syage to Chief Scientific Officer
--------------------------------------------------------------------------

- Jack Syage, previously President and COO, appointed Chief Scientific Officer effective June 17, 2024.
- Syage retains President title and reports to CEO James Sapirstein; compensation unchanged.
- Chief Operating Officer role vacated; no replacement named.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924073418/0001104659-24-073418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924073418/tm2417688d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-073418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer